Endeavor

A Random Blood Donation in New York Saves Moffitt Patient’s Life

A generous donor and a new post-transplant chemotherapy helped treat Maurice Poindexter’s chronic lymphatic leukemia

Hard-to-Treat Lymphoma Patients Benefit From New Immunotherapy

AZD0486 demonstrates high response rates in relapsed/refractory diffuse large B-cell lymphoma, including patients who failed CAR-T therapy

Moffitt Experts Share Latest Blood Cancer Advancements at ASH Annual Meeting

Novel therapies and innovative approaches take center stage in multiple hematologic malignancies

Moffitt Experts Conduct First Analysis on New Criteria for Chronic Myelomonocytic Leukemia

Study finds patients who were switched to a chronic myelomonocytic leukemia diagnosis based on the new criteria more so resembled myelodysplastic syndromes genetically.

Moffitt Researchers Find Breakthrough Treatment for Aggressive Blood Cancers

Promising combo therapy and innovative tracking techniques offer new hope for patients

Moffitt Study Finds New Genetic Clues to Resistance in Multiple Myeloma Treatments

Study reveals genetic markers that predict treatment resistance, offering potential for more personalized therapy plans

New CAR T-Cell Therapy Shows Promising Results for Advanced Multiple Myeloma

Early trial results show high success rates and manageable side effects

Drug Aims To Improve Transplant Success for Myelofibrosis Patients

Study shows giving patients fedratinib is safe and could help reduce chance of relapse

Drug Offers New Option for Patients With Rare Blood Disorders in ‘No Man’s Land’

Fedratinib is approved to treat myelofibrosis and could be effective in myelodysplastic/myeloproliferative neoplasms